A Practical Synthesis of (S)-tert-Butyl 3-Methyl-1,4-diazepane-1-carboxylate, the Key Intermediate of Rho–Kinase Inhibitor K-115

Abstract

A practical synthesis of (S)-tert-butyl 3-methyl-1,4-di­azepane-1-carboxylate has been established for supplying this key intermediate of Rho–kinase inhibitor K-115 in a multikilogram production. The chiral 1,4-diazepane was constructed by intramolecular Fukuyama–Mitsunobu cyclization of a N-nosyl diamino alcohol starting from the commercially available (S)- or (R)-2-aminopropan-1-ol. In the same manner, an enantiomeric pair of a structural isomer were prepared for demonstration of the synthetic utility.

Key words

1,4-diazepane - Fukuyama–Mitsunobu cyclization - cation­-exchange resin - asymmetric molecule - Rho–kinase inhibitor

• References

• 1 Ohshima T, Hidaka H, Shiratsuchi M, Onogi K, Oda T. PCT Int. Appl WO 2006057397, 2006 ; Chem. Abstr. 2006, 144, 495279.
• 2a Mizuno K, Koide T, Fujieda Y, Mori J, Kondo S, Matsumoto J, Hattori Y. Invest. Ophthalmol. Vis. Sci. 2007; 48: E-Abstract 4805
• 2b Mizuno K, Ohta M, Mori J, Ozawa T, Nishio M, Hidaka H, Sawanobori K. Invest. Ophthalmol. Vis. Sci. 2008; 49: E-Abstract 1640
• 2c Mizuno K, Isobe T, Koide T, Watanabe M, Kaneko Y, Inokuchi Y, Matsumoto J, Tanabe S. Invest. Ophthalmol. Vis. Sci. 2011; 52: E-Abstract 237
• 2d Tanihara H, Abe H, Kuwayama Y, Yamamoto T, Araie M. Invest. Ophthalmol. Vis. Sci. 2011; 52: E-Abstract 220
• 2e Yamamoto T, Abe H, Kuwayama Y, Tanihara H, Araie M. Invest. Ophthalmol. Vis. Sci. 2011; 52: E-Abstract 216
• 3 Gomi N, Ohgiya T, Shibuya K, Katsuyama J, Masumoto M, Sakai H. Heterocycles 2011; 83: 1771
• 4 Baxter CA, Cleator E, Brands KM. J, Edwards JS, Reamer RA, Sheen FJ, Stewart GW, Strotman NA, Wallace DJ. Org. Process Res. Dev. 2011; 15: 367
• 5 Revesz L, Bollbuck B, Buhl T, Eder J, Esser R, Feifel R, Heng R, Hiestand P, Jachez-Demange B, Loetscher P, Sparrer H, Schlapbach A, Waelchli R. Bioorg. Med. Chem. Lett. 2005; 15: 5160
• 6a Olsen CA, Christensen C, Nielsen B, Farah MM, Witt M, Clausen RP, Kristensen JL, Franzyk H, Jaroszewski JW. Org. Lett. 2006; 8: 3371
• 6b Ottesen LK, Olsen CA, Witt M, Jaroszewski JW, Franzyk H. Chem.–Eur. J. 2009; 15: 2966
• 7 Crestey F, Witt M, Jaroszewski JW, Franzyk H. J. Org. Chem. 2009; 74: 5652
• 8a Hidaka H, Matsuura A. PCT Int. Appl WO 1999020620, 1999 ; Chem. Abstr. 1999, 130, 306596.
• 8b The resulting mesylate was stored in the refrigerator overnight and showed significant decomposition from in situ generation of methanesulfonic acid which subsequently cleaved the N-Boc group.
• 9a Kan T, Kobayashi H, Fukuyama T. Synlett 2002; 697
• 9b Kan T, Fujiwara A, Kobayashi H, Fukuyama T. Tetrahedron 2002; 58: 6267
• 9c Suzuki M, Kambe M, Tokuyama H, Fukuyama T. J. Org. Chem. 2004; 69: 2831
• 9d Zapf CW, Del ValleJ. R, Goodman M. Bioorg. Med. Chem. Lett. 2005; 15: 4033
• 9e Hovinen J, Sillanpää R. Tetrahedron Lett. 2005; 46: 4387
• 9f Miyazaki T, Yokoshima S, Simizu S, Osada H, Tokuyama H, Fukuyama T. Org. Lett. 2007; 9: 4737
• 10a Fukuyama T, Jow C.-K, Cheung M. Tetrahedron Lett. 1995; 36: 6373
• 10b Maligres PE, See MM, Askin D, Reider PJ. Tetrahedron Lett. 1997; 38: 5253
• 10c Golantsov NE, Karchava AV, Yurovskaya MA. Chem. Heterocycl. Compd. 2008; 44: 263
• 11 Crestey F, Witt M, Frydenvang K, Stærk D, Jaroszewski JW, Franzyk H. J. Org. Chem. 2008; 73: 3566
• 12 Franzyk and co-workers’ conditions called for 15 equivalents of 3-aminopropan-1-ol; see ref. 7.

For a general review on aziridine chemistry, see:
• 13a Tanner D. Angew. Chem., Int. Ed. Engl. 1994; 33: 599
• 13b McCoull W, Davis FA. Synthesis 2000; 1347
• 13c Hu XE. Tetrahedron 2004; 60: 2701
• 14 Purification of the product was tedious due to the large amounts of triphenylphosphane oxide and diisopropyl hydrazine-1,2-dicarboxylate.
• 15a Gayo LM, Suto MJ. Tetrahedron Lett. 1997; 38: 513
• 15b Siegel MG, Hahn PJ, Dressman BA, Fritz JE, Grunwell JR, Kaldor SW. Tetrahedron Lett. 1997; 38: 3357
• 16a Koshio H, Hirayama F, Ishihara T, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Bioorg. Med. Chem. 2004; 12: 2179
• 16b Koshio H, Hirayama F, Ishihara T, Kaizawa H, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Uemura T, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Bioorg. Med. Chem. 2004; 12: 5415
• 16c Koshio H, Hirayama F, Ishihara T, Shiraki R, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Kaku S, Katayama N, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. Bioorg. Med. Chem. 2005; 13: 1305
• 16d Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, Seki N, Shiraki R, Shigenaga T, Iwatsuki Y, Moritani Y, Mori K, Kadokura T, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S. J. Med. Chem. 2011; 54: 8051
• 16e Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ. J. Med. Chem. 2010; 53: 5320
• 16f Pippel DJ, Young LK, Letavic MA, Ly KS, Naderi B, Soyode-Johnson A, Stocking EM, Carruthers NI, Mani NS. J. Org. Chem. 2010; 75: 4463
• 16g Pippel DJ, Mills JE, Pandit CR, Young LK, Zhong HM, Villani FJ, Mani NS. Org. Process Res. Dev. 2011; 15: 638
• 16h Wlodarczyk N, Broc-Ryckewaert DL, Gilleron P, Lemoine A, Farce A, Chavatte P, Dubois J, Pommery N, Hénichart J.-P, Furman C, Millet R. J. Med. Chem. 2011; 54: 1178
• 16i Peprah K, Zhu XY, Eyunni SV. K, Etukala JR, Setola V, Roth BL, Ablordeppey SY. Bioorg. Med. Chem. 2012; 20: 1671
• 16j Haddach M, Michaux J, Schwaebe MK, Pierre F, O’Brien SE, Borsan C, Tran J, Raffaele N, Ravula S, Drygin D, Siddiqui-Jain A, Darjania L, Stansfield R, Proffitt C, Macalino D, Streiner N, Bliesath J, Omori M, Whitten JP, Anderes K, Rice WG, Ryckman DM. ACS Med. Chem. Lett. 2012; 3: 135